Radiopharm Theranostics (RDPTF) Short-term Investments (2024)
Radiopharm Theranostics' (RDPTF) quarterly Short-term Investments came in at $40000.0 in Q4 2024, up 15073.94% quarter-over-quarter from $263.61 in Q2 2024.
Powered by 
Analysis
Radiopharm Theranostics (RDPTF) Short-term Investments (2024) Analysis & Trends
Radiopharm Theranostics (RDPTF) has reported Short-term Investments for 1 consecutive years, with $40000.0 the latest figure, recorded in Q4 2024.
- On a quarterly basis, Short-term Investments changed N/A year-over-year to $40000.0 in Q4 2024; TTM through Dec 2024 was $40000.0, a N/A change from a year earlier, with the FY2024 full-year figure at $40000.0, changed N/A from the prior year.
- Short-term Investments was $40000.0 for Q4 2024 at Radiopharm Theranostics, up from $263.61 in the prior quarter.
- Over five years, Short-term Investments peaked at $40000.0 in Q4 2024 and troughed at $263.61 in Q2 2024.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Amgen | 212.05 Bn | 198.06 Bn | 7.24 Bn |
| 2 | Gilead Sciences | 181.76 Bn | 178.58 Bn | 6.22 Bn |
| 3 | Vertex Pharmaceuticals | 132.46 Bn | 124.61 Bn | 2.84 Bn |
| 4 | Regeneron Pharmaceuticals | 82.66 Bn | 74.67 Bn | 3.93 Bn |
| 5 | Argenx Se | 61.56 Bn | 56.37 Bn | 1.37 Bn |
| 6 | Moderna | 54.69 Bn | 49.56 Bn | 52.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.18 Bn | 30.87 Bn | 992.69 Mn |
| 8 | Biogen | 31.46 Bn | 30.17 Bn | 1.96 Bn |
| 9 | Roivant Sciences | 30.15 Bn | 30.15 Bn | 1.16 Mn |
| 10 | Radiopharm Theranostics | 23.65 Mn | 23.60 Mn | -92,644.38 |